Pharma
Coempaken (Empagliflozin 12.5 mg / Metformin HCl 500 mg)
Antidiabetic combination; Empagliflozin 12.5 mg and Metformin 500 mg (28 tablets) for Type 2 Diabetes management.
Coempaken (Empagliflozin 12.5 mg / Metformin HCl 500 mg)
Coempaken is a combination medication containing Empagliflozin and Metformin HCl. Empagliflozin is an SGLT2 inhibitor that helps the kidneys get rid of glucose from your bloodstream. Metformin is a biguanide that lowers glucose production in the liver and improves insulin sensitivity. This pack contains 28 tablets (4x7 Tablets). It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Common side effects include urinary tract infections and gastrointestinal upset.
You May Also Like
Combination DPP-4 inhibitor and Biguanide; 50 mg/500 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50 mg/1000 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50mg/500mg Vildagliptin/Metformin tablets for Type 2 Diabetes control.
Triple antidiabetic combo; Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin ER 1000 mg (28 tablets) for Type 2 Diabetes.